

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FIL	ING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/663,360	7590 06/16/2006		Jian-yun Dong	22488-756	1654
75				EXAMINER	
Dr. Benjamin			HUMPHREY, LOUISE WANG ZHIYING		
Adler & Associates 8011 Candle Lane				ART UNIT	PAPER NUMBER
Houston, TX 77071			1648		
				DATE MAILED: 06/16/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)						
Office A Company of the Company of t	10/663,360	DONG, JIAN-YUN						
Office Action Summary	Examiner	Art Unit						
	Louise Humphrey, Ph.D.	1648						
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION (6(a). In no event, however, may a reply be tim ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).						
Status								
1) Responsive to communication(s) filed on								
,								
· <u> </u>	, _							
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Disposition of Claims								
4) Claim(s) 1-58 is/are pending in the application.								
4a) Of the above claim(s) is/are withdrawn from consideration.								
5) Claim(s) is/are allowed.								
6) Claim(s) is/are rejected.								
Claim(s) is/are objected to.								
8) Claim(s) <u>1-58</u> are subject to restriction and/or e	8) Claim(s) 1-58 are subject to restriction and/or election requirement.							
Application Papers								
9) The specification is objected to by the Examiner.								
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.						
Priority under 35 U.S.C. § 119								
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:								
 Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No 								
	• •							
	3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.								
Attachment(s)								
1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)						
2) DNotice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail D	ate						
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	6) Other:	Patent Application (PTO-152)						

Application/Control Number: 10/663,360 Page 2

Art Unit: 1648

This application contains claims directed to the following patentably distinct S

ecies in four genera:				
(A) anti-HIV agent:				
(1) nonnucleoside RT inhibitors;				
(2) nucleoside RT inhibitors;				
(3) protease inhibitors;				
(4) integrase inhibitors;				
(5) viral protein antagonists;				
(6) capsid lockers;				
(7) antisense or ribozyme oligonucleotides;				
(8) decoys of TAR sequence and RRE;				
(9) soluble CD4;				
(10) Gag and Env protein mutants, fusion / viral entry inhibitors;				
(B) order of addition of anti-HIV agent:				
(11) before the cell culture is contacted with the first HIV sample;				
(12) after the cell culture is contacted with the first HIV sample;				
(C) first cell culture:				
(13) tumor cell;				
(14) PBMC;				
(D) human cell naturally expressing cell surface co-receptors:				

(15) PBMC; and

(16) HUT78

Art Unit: 1648

The species are independent or distinct because their structures, functions, and modes of action are different; thus, each represents a patentably distinct subject matter. Furthermore, the examination of these species would require different searches in the scientific literature, which would not be coextensive. As such, it would be burdensome to search these species together.

Applicant is required under 35 U.S.C. §121 to elect a single disclosed species from each genus for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim 45 is generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species.

MPEP § 809.02(a).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions

Art Unit: 1648

unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. §103(a) of the other invention.

Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Louise Humphrey, Ph.D. whose telephone number is 571-272-5543. The examiner can normally be reached on Mon-Fri, 9:30 am - 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Louise Humphrey, Ph.D. Assistant Patent Examiner 13 June 2006

PRIMARY EXAMINER